Jude Fitzgibbon

I joined Queen Mary University of London as a Research Fellow in Medical Oncology in 1997 and am currently Professor of Personalised Cancer Medicine. I received my BA degree in Genetics at Trinity College Dublin in 1989 before completing my PhD studies on the Genetics of Tuberous Sclerosis at University College London in 1993. My major research focus is on Germinal Centre B cell malignancies and the (epi)genomic changes responsible for the onset and severity of these diseases. The Haemato-Oncology centre at Barts maintains one of the largest collections of sequential lymphoma tumor tissue repositories worldwide, that has allowed us to trace the genetic changes in these tumors over time. We have developed a mutational landscape of the Follicular Lymphoma genome, uncovered a highly complex pattern of tumor evolution, consistent with the existence of a common progenitor B cell population which we now believe is critical for propagating new episodes of disease. Our existing studies are focusing on early recurring tumor specific mutations and the development of a translational pipeline suitable for precision medicine as part of a UK wide initiative, where our group is concentrating on the histone methyltransferase EZH2 and the mTOR pathway. Our research is supported by a programme award from Cancer Research UK with significant other funding from Kay Kendall Leukaemia Fund and Bloodwise charities.